|
|
|
|
|
|
|
|
|
|
|
|
|
Equity capital |
Reserves |
Gains/losses recognized immediately in equity |
|
|
|
|||||
€ million |
General |
Subscribed |
Capital |
Retained |
Actuarial |
Available- |
Derivative |
Currency |
Equity |
Non- |
Equity |
Balance as of January 1, 2011 |
397.2 |
168.0 |
3,813.7 |
5,040.9 |
–370.4 |
–3.1 |
–61.1 |
1,344.6 |
10,329.8 |
42.0 |
10,371.8 |
Profit after tax |
– |
– |
– |
341.1 |
– |
– |
– |
– |
341.1 |
3.1 |
344.2 |
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
– |
21.6 |
13.3 |
–63.4 |
–28.5 |
–2.2 |
–30.7 |
Comprehensive income |
– |
– |
– |
341.1 |
– |
21.6 |
13.3 |
–63.4 |
312.6 |
0.9 |
313.5 |
Dividend payments |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–104.8 |
– |
– |
– |
– |
–104.8 |
– |
–104.8 |
Changes in scope of consolidation/ Other |
– |
– |
– |
–1.3 |
–0.1 |
– |
– |
– |
–1.4 |
0.1 |
–1.3 |
Balance as of March 31, 2011 |
397.2 |
168.0 |
3,813.7 |
5,275.9 |
–370.5 |
18.5 |
–47.8 |
1,281.2 |
10,536.1 |
43.0 |
10,579.1 |
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2012 |
397.2 |
168.0 |
3,813.7 |
5,248.7 |
–390.7 |
0.8 |
–94.6 |
1,304.0 |
10,447.1 |
46.3 |
10,493.4 |
Profit after tax |
– |
– |
– |
174.2 |
– |
– |
– |
– |
174.2 |
2.4 |
176.6 |
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
–1.0 |
– |
57.5 |
–19.2 |
37.3 |
–0.2 |
37.1 |
Comprehensive income |
– |
– |
– |
174.2 |
–1.0 |
– |
57.5 |
–19.2 |
211.5 |
2.3 |
213.8 |
Dividend payments |
– |
– |
– |
– |
– |
– |
– |
– |
– |
–0.7 |
–0.7 |
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–69.0 |
– |
– |
– |
– |
–69.0 |
– |
–69.0 |
Changes in scope of consolidation/ Other |
– |
– |
– |
0.6 |
– |
– |
– |
– |
0.6 |
–0.2 |
0.4 |
Balance as of March 31, 2012 |
397.2 |
168.0 |
3,813.7 |
5,354.5 |
–391.7 |
0.8 |
–37.1 |
1,284.8 |
10,590.2 |
47.6 |
10,637.8 |